Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis

Serious lung infections remain a major cause of morbidity among people with cystic fibrosis, a life-threatening genetic disorder characterized by persistent airway colonization and frequent antimicrobial exposure. Prolonged antibiotic use can alter the airway microbiome, promote antimicrobial resistance, and complicate efforts to select targeted therapies. Rapid and accurate identification of pathogens and resistance determinants is therefore essential for effective clinical management. New findings highlight how DNA sequencing can improve the detection and characterization of respiratory infections, supporting more precise treatment decisions.

Researchers at Flinders University examined the use of DNA sequencing reads to more accurately identify microbial infections in cystic fibrosis and other respiratory diseases. The approach is described in a study published in Clinical Microbiology Reviews on August 3, 2026, and is considered in the context of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies, which have transformed the course of the disease for many patients.

Image Credit: Adobe Stock

The researchers emphasize that comprehensive microbial surveillance using sequencing technologies will be important for understanding how CFTR modulators reshape the airway microbiome over time. By improving diagnostic precision and providing greater insight into pathogens and antimicrobial resistance, sequencing-based approaches could help clinicians reduce the risks associated with extensive antibiotic exposure and tailor treatment more effectively.

The technology centers on respiratory metagenomic sequencing and related read-level analyses, enabling researchers to characterize entire airway microbial communities rather than search for individual pathogens. According to the institution, sequencing can track shifts in the microbiome, detect infections more rapidly than traditional laboratory methods, and identify antimicrobial resistance.

The approach can also reveal community composition and diversity, strain-level variation, antimicrobial resistance genes, virulence determinants, and microbial metabolic functions. By analyzing these features directly from clinical samples, sequencing-based methods may accelerate organism identification and help guide more targeted antimicrobial treatment.

Potential implementation pathways include portable sequencing devices, some no larger than a cellphone and connected to a laptop, that could bring rapid testing into hospitals as well as remote and rural settings. Although these tools are already being adopted in select care environments, the authors note that further evaluation is needed before they can be integrated into routine clinical practice in Australia.

The technology may also have applications beyond cystic fibrosis, supporting earlier diagnosis and more precise treatment across a range of respiratory and other microbially driven conditions. Overall, the review highlights the potential of rapid sequencing workflows to enable real-time pathogen surveillance and more personalized antimicrobial strategies.

“DNA sequencing is transforming how we diagnose and manage infections, revealing entire microbial communities instead of single pathogens and paving the way for faster, more precise and personalized treatment,” said Rob Edwards, Professor of Bioinformatics at Flinders University.

“Respiratory metagenomic sequencing is already being introduced into intensive care units in the UK to provide faster diagnosis of severe respiratory infections and guide antimicrobial therapy,” said Dr. Jessica Carlson-Jones, research associate at the Flinders Accelerator for Microbiome Exploration (FAME).

Related Links
Flinders University